Tharimmune (THAR) Competitors $1.37 +0.02 (+1.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. CLDI, NXTC, RLYB, HOTH, BCTX, IMNN, BGXX, NERV, HCWB, and CLRBShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Calidi Biotherapeutics (CLDI), NextCure (NXTC), Rallybio (RLYB), Hoth Therapeutics (HOTH), BriaCell Therapeutics (BCTX), Imunon (IMNN), Bright Green (BGXX), Minerva Neurosciences (NERV), HCW Biologics (HCWB), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Calidi Biotherapeutics NextCure Rallybio Hoth Therapeutics BriaCell Therapeutics Imunon Bright Green Minerva Neurosciences HCW Biologics Cellectar Biosciences Calidi Biotherapeutics (NYSE:CLDI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Does the MarketBeat Community prefer CLDI or THAR? Tharimmune received 2 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/ATharimmuneOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of CLDI or THAR? 12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by company insiders. Comparatively, 10.0% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer CLDI or THAR? In the previous week, Calidi Biotherapeutics had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 0 mentions for Tharimmune. Calidi Biotherapeutics' average media sentiment score of 0.23 beat Tharimmune's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Tharimmune Neutral Which has stronger earnings & valuation, CLDI or THAR? Tharimmune has lower revenue, but higher earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K232.30-$29.22MN/AN/ATharimmuneN/AN/A-$9.32M-$7.88-0.17 Do analysts prefer CLDI or THAR? Calidi Biotherapeutics presently has a consensus target price of $10.00, indicating a potential upside of 2,350.98%. Tharimmune has a consensus target price of $17.00, indicating a potential upside of 1,140.88%. Given Calidi Biotherapeutics' higher possible upside, research analysts clearly believe Calidi Biotherapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CLDI or THAR more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Tharimmune N/A -167.63%-130.18% Which has more risk & volatility, CLDI or THAR? Calidi Biotherapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. SummaryCalidi Biotherapeutics beats Tharimmune on 8 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.65M$6.50B$5.34B$8.42BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.179.1526.8519.72Price / SalesN/A252.36387.23121.26Price / CashN/A65.8538.2534.62Price / Book0.016.456.774.51Net Income-$9.32M$144.21M$3.23B$248.32M7 Day Performance3.40%2.38%1.81%0.60%1 Month Performance18.10%4.50%10.93%13.18%1 Year Performance-71.98%-2.75%17.15%7.39% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune1.5371 of 5 stars$1.37+1.5%$17.00+1,140.9%-77.0%$3.65MN/A-0.172Gap UpCLDICalidi Biotherapeutics1.9305 of 5 stars$0.44-1.5%$15.00+3,332.5%N/A$12.63M$50,000.000.0038NXTCNextCure3.9566 of 5 stars$0.45+3.3%$3.50+680.4%-69.7%$12.58MN/A-0.2190Positive NewsGap DownRLYBRallybio1.8875 of 5 stars$0.30-1.0%$10.00+3,255.7%-79.8%$12.40M$636,000.00-0.1940HOTHHoth Therapeutics3.2958 of 5 stars$0.90-3.2%$4.00+344.8%-29.5%$12.24MN/A-0.684Analyst DowngradeGap DownBCTXBriaCell Therapeutics1.3184 of 5 stars$3.17+1.6%$32.00+909.5%-84.5%$11.76MN/A-0.248IMNNImunon1.5886 of 5 stars$0.80-1.9%$15.50+1,837.5%-72.3%$11.70M$500,000.00-0.4230News CoverageAnalyst ForecastGap UpBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownNERVMinerva Neurosciences2.9324 of 5 stars$1.63-0.1%$5.00+206.7%-41.1%$11.40MN/A-3.709News CoverageAnalyst ForecastGap UpHCWBHCW Biologics1.5714 of 5 stars$10.05+92.9%N/A-80.4%$11.29M$2.57M-10.0540Earnings ReportHigh Trading VolumeCLRBCellectar Biosciences2.3061 of 5 stars$0.24-9.1%$12.50+5,108.3%-92.3%$11.06MN/A-0.1410Analyst Forecast Related Companies and Tools Related Companies Calidi Biotherapeutics Competitors NextCure Competitors Rallybio Competitors Hoth Therapeutics Competitors BriaCell Therapeutics Competitors Imunon Competitors Bright Green Competitors Minerva Neurosciences Competitors HCW Biologics Competitors Cellectar Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
